Phathom Pharmaceuticals, Inc. (PHAT)
NASDAQ: PHAT · Real-Time Price · USD
10.67
-0.07 (-0.65%)
At close: Mar 6, 2026, 4:00 PM EST
10.46
-0.21 (-1.97%)
After-hours: Mar 6, 2026, 6:54 PM EST
Phathom Pharmaceuticals Stock Forecast
Stock Price Forecast
The 6 analysts with 12-month price forecasts for Phathom Pharmaceuticals stock have an average target of 19.5, with a low estimate of 5.00 and a high estimate of 28. The average target predicts an increase of 82.76% from the current stock price of 10.67.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Phathom Pharmaceuticals stock from 6 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Oct '25 | Nov '25 | Dec '25 | Jan '26 | Feb '26 | Mar '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 4 | 4 | 4 | 4 | 4 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 1 | 1 | 2 | 2 | 2 | 2 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 5 | 5 | 6 | 6 | 6 | 6 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Guggenheim | Guggenheim | Strong Buy Maintains $20 → $25 | Strong Buy | Maintains | $20 → $25 | +134.30% | Feb 27, 2026 |
| Barclays | Barclays | Hold Initiates $16 | Hold | Initiates | $16 | +49.95% | Dec 9, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $20 → $26 | Strong Buy | Maintains | $20 → $26 | +143.67% | Oct 31, 2025 |
| Craig-Hallum | Craig-Hallum | Strong Buy Maintains $12 → $17 | Strong Buy | Maintains | $12 → $17 | +59.33% | Jun 9, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $20 | Strong Buy | Reiterates | $20 | +87.44% | Jun 9, 2025 |
Financial Forecast
Revenue This Year
320.77M
from 175.11M
Increased by 83.18%
Revenue Next Year
517.82M
from 320.77M
Increased by 61.43%
EPS This Year
-1.00
from -3.03
EPS Next Year
1.00
from -1.00
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 343.4M | 579.3M | |||
| Avg | 320.8M | 517.8M | |||
| Low | 284.2M | 447.2M |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 96.1% | 80.6% | |||
| Avg | 83.2% | 61.4% | |||
| Low | 62.3% | 39.4% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | -0.76 | 1.56 | |||
| Avg | -1.00 | 1.00 | |||
| Low | -1.16 | 0.14 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | - | - | |||
| Avg | - | - | |||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.